Sunflower Pharmaceutical Group Co.,Ltd

002737

CNE100001WT7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
23.51 ^CNY	-0.84%		-4.59%	-9.51%

26/06	Sunflower Pharmaceutical Group Co.,Ltd Announces Board Appointments	CI
05/06	Sunflower Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend (Tax Included) (A Shares) for the Year 2023, Payable on 14 June 2024	CI

Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.

January 04, 2021 at 09:30 pm IST

From December 13, 2020 to December 31, 2020, the company has repurchased 3,838,503 shares, representing 0.66% for CNY 56.33 million. With this, the company has completed the repurchase of 3,838,503 shares, representing 0.66% for CNY 56.33 million under the buyback announced on December 24, 2020.

Latest news about Sunflower Pharmaceutical Group Co.,Ltd

Sunflower Pharmaceutical Group Co.,Ltd Announces Board Appointments	27/06	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend (Tax Included) (A Shares) for the Year 2023, Payable on 14 June 2024	06/06	CI
Sunflower Pharmaceutical Group Co.,Ltd Approves Cash Dividend for the Year 2023	01/06	CI
China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation	06/05	MT
Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2023	27/04	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Chinese Drug Regulator Accepts Application of Sunflower Pharma's Unit for Fexofenadine Hydrochloride Oral Suspension	19/02	MT
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	25/23/25	CI
Sunflower Pharma Buys Local Drug Distributor for 2.3 Million Yuan	04/23/04	MT
Sunflower Pharmaceutical Group Co.,Ltd agreed to acquire Hainan Huihai Pharmaceutical Co., Ltd. from Tonghua Huikang Biopharmaceutical Co., Ltd. and Kang Jia for CNY 2.3 million	02/23/02	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 7, 2023	31/23/31	CI
Sunflower Pharmaceutical Group Co.,Ltd Approves 2022 Profit Distribution Plan	09/23/09	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2022	12/23/12	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	09/22/09	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented on A Shares, Payable on 02 June 2022	26/22/26	CI
Sunflower Pharmaceutical Group Co.,Ltd Approves 2021 Profit Distribution Plan	17/22/17	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Sunflower Pharmaceutical Group Co.,Ltd Proposes Final Cash Dividend for the Year 2021	23/22/23	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	21/22/21	CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.	13/21/13	CI
Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback announced on December 24, 2020, has expired with 3,838,503 shares, representing 0.66% for CNY 56.33 million.	13/21/13	CI

Chart Sunflower Pharmaceutical Group Co.,Ltd

Duration

Period

Chart Sunflower Pharmaceutical Group Co.,Ltd

More charts

Company Profile

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD	-9.51%	1.91B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.54B
OTSUKA HOLDINGS CO., LTD.	+34.52%	24.51B
SANDOZ GROUP AG	+27.12%	16.48B
CIPLA LIMITED	+21.19%	14.66B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.3B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.08%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals

Sunflower Pharmaceutical Group Co.,Ltd

Equities

002737

CNE100001WT7

Pharmaceuticals

Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.

Latest news about Sunflower Pharmaceutical Group Co.,Ltd

Chart Sunflower Pharmaceutical Group Co.,Ltd

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals